Skip to main content
PRISM BioLab Co.,LTD logo

PRISM BioLab Co.,LTD — Investor Relations & Filings

Ticker · 206A ISIN · JP3833190006 T Manufacturing
Open in API
Filings indexed 15 across all filing types
Latest filing 2025-12-24 Regulatory Filings
Country JP Japan
Listing T 206A

About PRISM BioLab Co.,LTD

https://prismbiolab.com/ja/

PRISM BioLab is a biotechnology company specializing in drug discovery and development. It utilizes its proprietary PepMetics® technology platform to create orally available, small molecule drugs that target protein-protein interactions (PPIs), which are often considered 'undruggable'. The platform designs molecules that mimic key peptide structures, such as α-helices and β-turns, to modulate these interactions. The company's primary mission is to develop novel therapeutics for intractable diseases that currently lack effective treatments. PRISM BioLab advances its pipeline through both internal research programs and strategic collaborations with pharmaceutical partners.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan. It serves as a formal certification by the CEO regarding the accuracy of the company's Annual Securities Report (Yukashoken Hokokusho). Since it is a regulatory filing required by law to accompany financial reporting but does not constitute the financial report itself, and given the specific nature of this certification, it falls under the general regulatory filing category.
2025-12-24 Japanese
有価証券報告書－第14期(2024/10/01－2025/09/30)
Annual Report Classification · 100% confidence The document is a formal '有価証券報告書' (Annual Securities Report) filed with the Kanto Local Finance Bureau in Japan. It covers a specific fiscal year (第14期, 2024-10-01 to 2025-09-30) and includes detailed financial statements, management analysis, and corporate information. This corresponds to the Japanese equivalent of a 10-K filing. FY 2025
2025-12-24 Japanese
臨時報告書
Major Shareholding Notification Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report or Timely Disclosure Report) in the header and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related regulations concerning a change in a major shareholder. Section 2 details the change, showing the shareholder's voting rights percentage before and after the event, and the date of the change (July 9, 2025). This structure and content strongly indicate a regulatory filing related to a significant change in shareholding, which aligns best with the 'Major Shareholding Notification' (MRQ) definition, as it reports changes in significant share ownership levels crossing thresholds. Although it is a Japanese regulatory filing, MRQ is the closest fit among the provided codes for a major shareholder change report.
2025-07-17 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the Representative Director of PRISM BioLab, confirming the accuracy of the contents of the semi-annual report. Per the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a report (like a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 14
2025-05-14 Japanese
半期報告書－第14期(2024/10/01－2025/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains comprehensive financial statements, management analysis (MD&A), and corporate information for the interim period (October 1, 2024, to March 31, 2025). This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-05-14 Japanese
内部統制報告書－第13期(2023/10/01－2024/09/30)
Governance Information Classification · 100% confidence The document explicitly states in the header section (【提出書類】) that it is an "内部統制報告書" (Internal Control Report) based on Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法). Section 1 discusses the framework for internal controls over financial reporting, Section 2 details the scope and procedures based on a specific fiscal year-end date (2024年９月30日), and Section 3 provides the evaluation result. This content perfectly matches the description of an Audit Report / Information (AR), which covers internal or regulatory stress tests and applied accounting principles, distinct from the full Annual Report (10-K).
2024-12-27 Japanese

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.